

Alina Chen MacMillan Group Meeting Literature Talk March 8th, 2022



What is Rheumatoid Arthritis? symptoms & causes



Deane, K.D.; et al. Arthritis & Rheumatology **2021**, 73, 2, 181. Bullock, J.; et. al.; *Med Princ Pract.* **2019**, 27, 6, 501. What is Rheumatoid Arthritis? symptoms & causes



eventually leads to cartilage damage and bone erosion also affects internal organs: skin, eyes, heart, etc.

Bullock, J.; et. al.; *Med Princ Pract.* 2019, 27, 6, 501.

What is Rheumatoid Arthritis? symptoms & causes



Arthritis Research | Arthritis National Research Foundation, 7 Sept. 2019.

What is Rheumatoid Arthritis? diagnosis



- May proceed rapidly, or take months/years
- Earlier treatment prevents development of RA
- "Early" stage of RA not defined or universally agreed

What is Rheumatoid Arthritis? diagnosis

2010 American College of Rheumatology/Eroean League against Rheumatism



What is Rheumatoid Arthritis? Treatment

First line: relieve pain and decrease inflammation



Nonsteroidal anti-inflammatory drugs (NSAIDs)



Steroids

What is Rheumatoid Arthritis? Treatment

Second line: promote remission





Disease-modifying anti-rheumatic drugs (DMARDs)

TNF α inhibitor



B-cell depletion and inhibition antibodies

Gun, Q.; et al Bone Res. 2018, 6, 15.

What is Rheumatoid Arthritis? Treatment

Second line: promote remission





B-cell depletion and inhibition antibodies

Gun, Q.; et al Bone Res. 2018, 6, 15.



What is Rheumatoid Arthritis? diagnosis

2010 American College of Rheumatology/Eroean League against Rheumatism



Citrullination and Citrullinated Peptides

anti-citrullinated peptide/protein antibodies (ACPA)





- 95~98% specificity to RA patients
- precede onset of clinical symptoms by years
- related to more severe and erosive phenotype

Citrullination and Citrullinated Peptides history





Citrullination and Citrullinated Peptides history









Filaggrin

Swiss-Model: 4PCW Van Venrooij, W.J.; *et al. J. Clin. Invest.* **1998**, 101, 1, 273.



Prof. Walther J. Van Venrooij



Egawa, G.; *et al. J. Allergy Clin. Immunol.* **2016**, 138, 2, 350. Van Venrooij, W.J.; *et al. J. Clin. Invest.* **1998**, 101, 1, 273.



Prof. Walther J. Van Venrooij





Van Venrooij, W.J.; et al. J. Clin. Invest. 1998, 101, 1, 273.

Citrullination and Citrullinated Peptides hypercitrullination in RA patients



Protein citrullination probed across 12 RA patients synovial tissues and SF Hypercitrullination seen across almost all

Citrullination and Citrullinated Peptides scope of citrullinated proteins

>100 citrullinated proteins identified



RCSB PDB: 6EC0; 1LWU; 5CVA

Darrah, E.; et al. Curt Opin Rheumatol. 2018 30, 1, 72.

Peptidylarginine deiminase (PAD)



The PAD Family





- expressed in: white blood cells
 - resides in cell nucleus
- citrullinates histones

positively charged

neutral





positively charged neutral H_2N irreversible? L_2^{2+} , reductive environment H_2N PAD H_2N peptide arginine peptide citrulline

PAD activity Ca²⁺ threshold: 10 μ M

cytosolic Ca²⁺: 0.1 μ**M**

Van Venrooij, W.J.; et al. Ann Rheum Dis 2004 63, 373.

How can PAD be activated?

Why do we find PAD extracellularly?

Van Venrooij, W.J.; et al. Ann Rheum Dis 2004 63, 373.

Citrullination and Citrullinated Peptides hypercitrullination in RA patients



Protein citrullination probed across 12 RA patients synovial tissues and SF Hypercitrullination seen across almost all







Hypercitrullination





Hypercitrullination













Membrane lesion induced Ca²⁺ influx is most responsible for hypercitrullination



Anti-Citrullinated Peptide/Protein Antibodies

ACPA



- 95~98% specificity to RA patients
- precede onset of clinical symptoms by years
- related to more severe and erosive phenotype

Anti-Citrullinated Peptide/Protein Antibodies



ACPA evolves overtime to become less specific

Anti-Citrullinated Peptide/Protein Antibodies general immune response pathways



Anti-Citrullinated Peptide/Protein Antibodies macrophage activation



monocyte activation

- Binds to citrullinated proteins cell surface
- Activates macrophages, monocytes, lymphocytes
- Increases TNFα (cytokine) production
- Alternatively, it activates TLR4

Anti-Citrullinated Peptide/Protein Antibodies neutrophil activation



- Immune complex binds to Fcγ receptors
 - Activates neutrophils
- Neutrophile degranulation, ROS release
- Initiate cytokine & chemokine cascade

Wu, C.; et al. Int. J. Mol. Sci. 2020, 21, 4015.

Anti-Citrullinated Peptide/Protein Antibodies Interaction with osteoclast

osteoclast



- Large multinucleated cell
- Causes bone dissolution and absorption
- ACPA promotes osteoclast activation & deffrentiation
- May be independent of antigen binding

Wu, C.; et al. Int. J. Mol. Sci. 2020, 21, 4015.

Anti-Citrullinated Peptide/Protein Antibodies







- Tested against sera from 927 RA patients and 461 healthy controls
 - 98% specificity was aimed for
- ACPA were isolated from patients and pre-incubated with fibrinogen
 - Performed anti-CCP2 competitive ELISA

Potential Therapeutics peptide inhibition of ACPA

a ACPA pool I





84% inhibition IC 50 : 59 μ M \pm 8

b ACPA pool II

Fibrinogen a chain 573 peptide



50% inhibition IC 50 : 548 μ M \pm 100

Potential Therapeutics peptide inhibition of ACPA



92% inhibition IC 50 : 28 μ M \pm 5

Cyclic citrullinated peptide showed enhanced reactivity

Fernandes-Cerqueira, C.; et al. Arthiritis Research& Therapy. 2015, 17, 155.

Potential Therapeutics peptide inhibition of ACPA

[Cit573]fibrinogen(563–583)



Potential Therapeutics peptide inhibition of ACPA

ACPA pool I: 79% inhibition IC₅₀: 20μM

SFTI-1

ACPA pool II: 61% inhibition IC₅₀: 87μ**M**

enhanced stability & sunflower trypsin inhibitor structural rigidity ACPA binding epitope aCCP2 IgG fibrinogen



formation of IC

hypercitrullination



formation of IC

hypercitrullination



formation of IC

